| Non-Small Cell Lung Carcinoma
Braftovi vs Xalkori
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Braftovi vs Xalkori with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXalkori has a higher rate of injection site reactions vs Braftovi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xalkori but not Braftovi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Braftovi
Xalkori
At A Glance
Oral
Once daily
BRAF inhibitor
Oral
Twice daily
ALK/ROS1 inhibitor
Indications
- melanoma
- Colorectal Carcinoma
- Non-Small Cell Lung Carcinoma
- Non-Small Cell Lung Carcinoma
- Ki-1+ Anaplastic Large Cell Lymphoma
- Inflammatory Myofibroblastic Tumor
Dosing
melanoma, Non-Small Cell Lung Carcinoma 450 mg (six 75 mg capsules) orally once daily in combination with binimetinib until disease progression or unacceptable toxicity.
Colorectal Carcinoma 300 mg (four 75 mg capsules) orally once daily until disease progression or unacceptable toxicity, in combination with biweekly cetuximab and mFOLFOX6 or FOLFIRI, or weekly cetuximab.
Non-Small Cell Lung Carcinoma Adults: 250 mg orally twice daily until disease progression or unacceptable toxicity.
Ki-1+ Anaplastic Large Cell Lymphoma Pediatric patients 1 year of age and older and young adults: 280 mg/m2 orally twice daily (BSA-based dosing) until disease progression or unacceptable toxicity.
Inflammatory Myofibroblastic Tumor Adults: 250 mg orally twice daily; pediatric patients 1 year of age and older: 280 mg/m2 orally twice daily (BSA-based dosing), until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=25%) Fatigue, nausea, vomiting, diarrhea, abdominal pain, arthralgia, peripheral neuropathy, decreased appetite, rash, constipation, musculoskeletal pain, hemorrhage, pyrexia.
Serious New primary malignancies, cardiomyopathy, hepatotoxicity, hemorrhage, uveitis, QT prolongation, embryo-fetal toxicity.
Most common (>=25%) Vision disorders, nausea, diarrhea, vomiting, edema, constipation, elevated transaminases, fatigue, decreased appetite, upper respiratory infection, dizziness, neuropathy.
Serious Hepatotoxicity, interstitial lung disease/pneumonitis, QT interval prolongation, bradycardia, severe visual loss, gastrointestinal toxicity (in pediatric/young adult ALCL or pediatric IMT patients).
Postmarketing Increased blood creatine phosphokinase.
Pharmacology
Encorafenib is a kinase inhibitor that targets BRAF V600E as well as wild-type BRAF and CRAF, blocking constitutively activated BRAF kinase signaling driven by BRAF V600 mutations that stimulates tumor cell growth; in combination with binimetinib, it targets two kinases in the RAS/RAF/MEK/ERK pathway for greater anti-tumor activity.
Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, ROS1, c-Met, and RON; it blocks ALK fusion protein-driven oncogenic signaling, inhibiting tumor cell proliferation and survival.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Braftovi
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Xalkori
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Braftovi
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (0/8)
Xalkori
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Braftovi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Xalkori
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Braftovi Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Non-Small Cell Lung Cancer (NSCLC)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BraftoviView full Braftovi profile
XalkoriView full Xalkori profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.